MYMETICS CORP

MYMX 4 | $0.0016 0.0% 4.8M

(0.0% 1d) (0.0% 1m) (-77.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1988.71% volume)
Earnings Calendar:
Market Cap: $ 486,012

Sec Filling | Patents | 8 employees

mymetics corporation (otcqb: mymx) is a swiss based biotechnology company, with a research lab in the netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. it has currently has 5 vaccines in its pipeline: hiv-1/aids, intra-nasal influenza, malaria, herpes simplex virus and the rsv vaccine. mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. the company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. the company’s unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including astellas pharma, path-mvi and the bill an

injection influenza pathogens vaccine

add to watch list Paper trade email alert is off

NightHawk Biosciences Inc

NHWK | $0.4135 0.0% 170K

Manufacturing

(0.0% 1d) (0.0% 1m) (-47.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 10,784,862
https://www.heatbio.com
Sec Filling | Patents | 39 employees

(US) Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

antibody vaccine infectious disease cancer t-cell covid hepatitis

add to watch list Paper trade email alert is off

NRX Pharmaceuticals Inc

NRXP | $3.08 1.99% 1.95% 230K

Manufacturing

(0.0% 1d) (522.7% 1m) (403.2% 1y) (0.0% 2d) (-27.8% 3d) (-38.4% 7d) (496.91% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 294,755,322
https://www.bigrockpartners.com/spac/spac_aboutus.html
Sec Filling | Patents | 2 employees

(US) Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Big Rock Partners' management team includes Richard Ackerman, Chairman, President, and Chief Executive Officer, and Bennett Kim, Chief Financial Officer, Chief Investment Officer, Corporate Secretary and Director.

covid treatment vaccine acquisitions zyesami aviptadil blank check

add to watch list Paper trade email alert is off

Valneva SE - ADR

VALN | $7.96 -2.09% -2.13% 8.5K

Manufacturing

(0.0% 1d) (14.5% 1m) (-20.8% 1y) (0.0% 2d) (4.9% 3d) (-4.4% 7d) (71.64% volume)
Earnings Calendar:
Market Cap: $ 552,870,325
https://valneva.com/
Sec Filling | Patents | 2021 employees

(FR) Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.

vaccine ixchiq chikungunya

add to watch list Paper trade email alert is off

Evaxion Biotech A/S - ADR

EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

(0.0% 1d) (39.3% 1m) (212.6% 1y) (0.0% 2d) (3.4% 3d) (2.9% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 21,903,231
https://www.evaxion-biotech.com
Sec Filling | Patents | 2020 employees

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.

vaccine cancer immunotherapy infectious disease injection batteries skin

add to watch list Paper trade email alert is off

Imunon Inc

IMNN | News | $1.16 3.11% 3.02% 95K

Manufacturing

(0.0% 1d) (46.2% 1m) (-9.5% 1y) (0.0% 2d) (0.0% 3d) (-22.4% 7d) (57.5% volume)
Earnings Calendar:
Market Cap: $ 10,903,755
https://www.celsion.com
Sec Filling | Patents | 27 employees

(US) Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

vaccine treatment ovarian cancer cancer hepatitis

add to watch list Paper trade email alert is off